Fredun Pharmaceuticals Ltd Stock Price Today (NSE: FREDUN)
Fundamental Score
Fredun Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Fredun Pharmaceuticals Ltd share price today is ₹987.00, up +5.54% on NSE/BSE as of 31 July 2026. Fredun Pharmaceuticals Ltd (FREDUN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.56K (Cr). The 52-week high for FREDUN share price is ₹2950.00 and the 52-week low is ₹851.70. At a P/E ratio of 46.92x, FREDUN is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 15.81% and a debt-to-equity ratio of 0.80.
Fredun Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Fredun Pharmaceuticals Ltd share price chart: -64.82% return over the past month. 52-week high ₹2950.00, 52-week low ₹851.70.
Fredun Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹970.00 | ₹999.00 | ₹955.00 | ₹987.00 | 43.23K (Cr) | |
| ₹917.00 | ₹948.95 | ₹910.00 | ₹935.15 | 30.94K (Cr) | |
| ₹903.00 | ₹925.00 | ₹887.00 | ₹907.20 | 42.93K (Cr) | |
| ₹905.10 | ₹921.00 | ₹860.00 | ₹903.85 | 23.36K (Cr) | |
| ₹907.70 | ₹924.40 | ₹876.00 | ₹906.70 | 16.74K (Cr) | |
| ₹895.00 | ₹909.95 | ₹851.70 | ₹895.20 | 19.02K (Cr) | |
| ₹878.00 | ₹927.00 | ₹865.00 | ₹896.30 | 19.55K (Cr) | |
| ₹926.65 | ₹940.00 | ₹902.60 | ₹916.60 | 20.61K (Cr) | |
| ₹931.00 | ₹950.00 | ₹859.75 | ₹926.65 | 43.81K (Cr) | |
| ₹999.00 | ₹999.00 | ₹943.00 | ₹955.20 | 21.10K (Cr) |
Fredun Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2790.00 | ₹2950.00 | ₹851.70 | ₹987.00 | -64.62% | |
| ₹2490.00 | ₹2825.00 | ₹2199.35 | ₹2814.30 | +13.02% | |
| ₹2240.10 | ₹2620.00 | ₹2164.95 | ₹2495.55 | +11.40% | |
| ₹1667.20 | ₹2278.85 | ₹1667.20 | ₹2230.90 | +33.81% | |
| ₹1515.15 | ₹1840.00 | ₹1452.50 | ₹1671.80 | +10.34% | |
| ₹1560.00 | ₹1944.00 | ₹1508.00 | ₹1624.45 | +4.13% | |
| ₹1570.00 | ₹1627.00 | ₹1362.15 | ₹1538.30 | -2.02% | |
| ₹1979.95 | ₹1999.00 | ₹1502.30 | ₹1578.30 | -20.29% | |
| ₹1476.00 | ₹1971.25 | ₹1471.10 | ₹1923.45 | +30.32% | |
| ₹1346.00 | ₹1785.00 | ₹1281.00 | ₹1539.15 | +14.35% | |
| ₹1173.00 | ₹1355.00 | ₹1151.00 | ₹1314.65 | +12.08% | |
| ₹1019.80 | ₹1329.00 | ₹972.00 | ₹1150.25 | +12.79% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Overvalued micro-cap pharma banking on a pet care pivot; governance issues linger.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Fredun Pharma closed its trading window for insiders on April 1st ahead of FY26 results. The board meeting to approve the audited financials is pending. MarketsMojo downgraded the stock to 'Hold' on April 6th, citing mixed technical signals despite strong fundamentals. An investor meeting was rescheduled to March 25th and held virtually.
CORE STORY (THE REAL GAME)
Fredun is being priced as a high-growth micro-cap pharma play, with a recent diversification kicker into pet care. The market is betting on continued revenue and profit growth driven by new products and geographic expansion.
- Q3 results were strong, but backward-looking
- Credit rating upgrade already priced in
- Micro-cap liquidity is always a risk
- Strong FY26 results beat estimates
- Successful integration of Wagr.ai
- New large order wins
- Micro-cap: liquidity risk is high
- High P/E: valuation is stretched
- Past SEBI order: governance concerns
FII and DII holdings are negligible; promoter holding stable.
Indian pharma sector has tailwinds from API backward integration and export diversification.
No Free Cash Flow data available
Next 3-6 months hinge on FY26 results and progress on Wagr.ai integration. Watch for any further regulatory scrutiny.
Primary Thesis Risk
Failure to execute pet care strategy and stretched valuation will lead to a correction.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Fredun Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Fredun Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of FREDUN across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (15.81%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.49%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Robust Profit Growth (56.58%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (27.26%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (36.54% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (64.50% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (75.23% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 46.92x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Interest Coverage (2.21x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-122.53 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 3.87%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Fredun Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Fredun Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Fredun Pharmaceuticals LtdFredun Pharmace...Selected✓ FREDUN • 539730 | 66.8/100 | ₹987.00₹987 | ₹1558.22₹1558.22 | 46.92Average 46.9 Average | 15.81%Good 15.81% Good | 21.49%Excellent 21.49% Excellent | 0.80Good 0.8 Good | 75.23%Excellent 75.23% Excellent | 36.54%Excellent 36.54% Excellent | 0.01% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Fredun Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for FREDUN — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹44.83 | ₹1578.30 | 35.2x |
| FY 2024 | ₹33.32 | ₹737.25 | 22.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Fredun Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for FREDUN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
27.26%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
56.58%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
36.54%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
75.23%
Compounded annual net profit growth over 5 years
Fredun Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for FREDUN — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Fredun Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Fredun Pharmaceuticals Ltd (FREDUN) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Fredun Pharmaceuticals Ltd
About FREDUN (Fredun Pharmaceuticals Ltd)
Fredun Pharmaceuticals Ltd is a globally-minded pharmaceutical company dedicated to improving health outcomes through the development, manufacturing, and distribution of a diverse ...range of healthcare products. With a firm commitment to innovation and quality, FREDUN operates at the intersection of science and wellness, offering effective solutions to address a spectrum of medical needs. The company's reach extends across continents, delivering essential medicines and health support to underserved communities and established markets alike. By prioritizing research and development and adhering to stringent international standards, FREDUN aims to be a trusted partner in healthcare, empowering individuals to live healthier and more fulfilling lives. FREDUN's product portfolio spans across a broad spectrum of therapeutic categories, including both prescription and over-the-counter medications, as well as specialized dietary supplements and nutraceuticals. The company meticulously crafts its formulations using advanced technologies and rigorously tested ingredients to ensure optimal efficacy and safety. From addressing common ailments to managing chronic conditions, FREDUN provides reliable and accessible healthcare options for a variety of patient needs. Committed to accessibility and affordability, FREDUN strives to bridge the gap between cutting-edge pharmaceutical advancements and the needs of diverse populations around the world. Beyond manufacturing and distributing pharmaceutical products, FREDUN is dedicated to fostering long-term health improvements through educational initiatives and community engagement. By partnering with healthcare professionals and organizations, the company seeks to promote awareness about preventative care and disease management, empowering individuals to take proactive steps towards a healthier lifestyle. FREDUN is deeply invested in sustainable practices and ethical operations, striving to minimize its environmental footprint and contribute positively to the communities it serves. The company envisions a future where quality healthcare is accessible to all, and it is dedicated to working tirelessly to make that vision a reality.
Company Details
Key Leadership
Corporate Events
Latest News
FREDUN Share Price: Frequently Asked Questions
What is the current share price of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd (FREDUN) trades at ₹987.00 on NSE and BSE. Market cap ₹1.56K (Cr). Educational data only.
What is the P/E ratio of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd has a P/E of 46.92x vs industry average 34.89x.
What is the Bull Run score for Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd has a Bull Run score of 66.8/100 based on 25+ financial parameters.
Does Fredun Pharmaceuticals Ltd pay dividends?
Fredun Pharmaceuticals Ltd has a dividend yield of 0.01%. Past dividends don't guarantee future payments.
What is the ROE of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd has ROE of 15.81%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd has debt-to-equity of 0.80.
Is Fredun Pharmaceuticals Ltd a good investment?
Bull Run gives Fredun Pharmaceuticals Ltd a score of 66.8/100. This is not investment advice — consult a SEBI-registered advisor.